Lecanemab

Eisai, in partnership with BioArctic AB, is launching Leqembi in Europe, starting with Austria and Germany. Leqembi, approved by the European Commission in April 2025, is the first therapy targeting the underlying cause of Alzheimer’s disease (AD). Indicated for early AD patients (ApoE ε4 non-carriers or heterozygotes) with confirmed amyloid pathology, Leqembi demonstrated a 31% reduction in clinical decline in trials. Lecanemab selectively binds to aggregated soluble and insoluble forms of amyloid-beta (Aβ). It has already been approved in U.S., Japan, EU, China, etc. Common adverse reactions include infusion-related reactions and ARIA.